Sort
21,453 grants matching “tuberculosis”
Thioesterase Inhibitors of Mycolic Acid Biosynthesis as Antitubercular Agents
$219,989Courtney C Aldrich · University Of Minnesota · R21 · FY2008 · AI
Enhanced POC assay for TB in HIV-infected children based on the ultrasensitive detection of the urinary form of the lipoarabinomannan antigen
$219,988Abraham Pinter · Rbhs-New Jersey Medical School · R01 · FY2022 · AI
Optimizing vaccine science to improve the outcome of tuberculosis treatment
$219,863Selvakumar Subbian · Rbhs-New Jersey Medical School · R01 · FY2022 · AI
Host Defenses and Susceptibility to Tuberculosis
$219,840Gerard J Nau · University Of Pittsburgh At Pittsburgh · R21 · FY2006 · AI
INTERDISCIPLINARY PROGRAM IN BACTERIAL PATHOGENESIS
$219,837Ferric C Fang · University Of Washington · T32 · FY2018 · AI
Effect Ultraviolet Radiation on Latent M. tuberculosis Infection in Guinea Pigs
$219,750Amminikutty Jeevan · Texas A&M University Health Science Ctr · R21 · FY2009 · AI
Monitoring Treatment Efficacy in Leprosy
$219,686Charlotte Avanzi · Colorado State University · R21 · FY2022 · AI
Effects of carbon dioxide on M. tuberculosis growth and gene expression
$219,544Kathleen A. McDonough · Wadsworth Center · R21 · FY2008 · AI
Structural Biology of Protein Complexes of Mtb
$219,349David S Eisenberg · Texas A&M University · P01 · FY2015 · AI
Localization and assembly of the M. tuberculosis ESX-1 secretory apparatus
$219,340Keith M Derbyshire · Wadsworth Center · R21 · FY2011 · AI
Post Translation Regulation in Mycobacteria
$219,300Luiz E Bermudez · Oregon State University · R21 · FY2007 · AI
An Inhaled Clofazimine Formulation for the Treatment of Tuberculosis
$219,242Jared Franklin Mike · Lynntech, Inc. · R43 · FY2019 · AI
VACCINE AND TREATMENT EVALUATION UNIT: Phase 4 Tuberculosis Therapeutics Trial
$219,240Daniel Hoft · Saint Louis University · N01 · FY2017 · AI
A systematic method for Gain-of Function genetics in mycobacteria
$219,183Christopher M Sassetti · Univ Of Massachusetts Med Sch Worcester · R21 · FY2020 · AI
Marine Fatty Acids as New Antifungal, Antimycobacterial, and Topo-l Agents
$219,175Nestor Manuel Carballeira · University Of Puerto Rico Rio Piedras · SC1 · FY2008 · GM
Molecular mechanisms of TB exposure outcomes among HIV-infected children
$219,140Gabriel Anabwani · Botswana Baylor Child/Clincal Ctr/Excell · U54 · FY2018 · AI
A multi-scale and multi-system approach to understand granuloma formation in TB
$219,090Jennifer Jean Linderman · University Of Michigan At Ann Arbor · R33 · FY2008 · HL
Specific anti-TB compounds from uncultured bacteria
$219,069Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R43 · FY2015 · AI
Non-competitive proteasome inhibitors to treat chronic, drug-resistant tuberculosis
$219,058Robert B Abramovitch · Michigan State University · R21 · FY2017 · AI
INTERDISCIPLINARY PROGRAM IN BACTERIAL PATHOGENESIS
$219,057Ferric C Fang · University Of Washington · T32 · FY2019 · AI
RAPID: The Changing Nature of Work: Dynamic Reconfiguration and Visualization in the Context of Covid-19 Contact Tracing
$219,051John R Hollenbeck · Michigan State University · · FY2020 · SBE
Multidisciplinary Training Program in Pediatric Pulmonary
$219,025Pamela L. Zeitlin · Johns Hopkins University · T32 · FY2010 · HL
Strategy for anti-tuberculosis therapy
$219,000Luiz E Bermudez · Oregon State University · R21 · FY2014 · AI
MOLECULAR BIOLOGY OF UNIQUE WALL LIPIDS OF MYCOBACTERIA
$218,961University Of Central Florida · R01 · FY2002 · AI
Anti-inflammatory promoting commensal E. coli
$218,903Cammie Lesser · Massachusetts General Hospital · R21 · FY2013 · AI